Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000697914 | Breast | IDC | response to oxidative stress | 83/1434 | 446/18723 | 2.36e-14 | 7.06e-12 | 83 |
GO:001603214 | Breast | IDC | viral process | 75/1434 | 415/18723 | 1.98e-12 | 4.02e-10 | 75 |
GO:000030214 | Breast | IDC | response to reactive oxygen species | 46/1434 | 222/18723 | 4.12e-10 | 4.59e-08 | 46 |
GO:005079214 | Breast | IDC | regulation of viral process | 36/1434 | 164/18723 | 6.55e-09 | 5.03e-07 | 36 |
GO:004254213 | Breast | IDC | response to hydrogen peroxide | 32/1434 | 146/18723 | 4.65e-08 | 3.02e-06 | 32 |
GO:003410114 | Breast | IDC | erythrocyte homeostasis | 27/1434 | 129/18723 | 1.34e-06 | 5.75e-05 | 27 |
GO:000226214 | Breast | IDC | myeloid cell homeostasis | 30/1434 | 157/18723 | 2.64e-06 | 1.01e-04 | 30 |
GO:005067313 | Breast | IDC | epithelial cell proliferation | 60/1434 | 437/18723 | 7.13e-06 | 2.15e-04 | 60 |
GO:003009914 | Breast | IDC | myeloid cell differentiation | 54/1434 | 381/18723 | 8.07e-06 | 2.39e-04 | 54 |
GO:005067812 | Breast | IDC | regulation of epithelial cell proliferation | 54/1434 | 381/18723 | 8.07e-06 | 2.39e-04 | 54 |
GO:000941013 | Breast | IDC | response to xenobiotic stimulus | 62/1434 | 462/18723 | 1.05e-05 | 2.88e-04 | 62 |
GO:005159114 | Breast | IDC | response to cAMP | 20/1434 | 93/18723 | 2.00e-05 | 4.91e-04 | 20 |
GO:003166714 | Breast | IDC | response to nutrient levels | 62/1434 | 474/18723 | 2.33e-05 | 5.57e-04 | 62 |
GO:000181911 | Breast | IDC | positive regulation of cytokine production | 61/1434 | 467/18723 | 2.81e-05 | 6.58e-04 | 61 |
GO:000961211 | Breast | IDC | response to mechanical stimulus | 34/1434 | 216/18723 | 4.59e-05 | 1.03e-03 | 34 |
GO:004668312 | Breast | IDC | response to organophosphorus | 24/1434 | 131/18723 | 5.22e-05 | 1.12e-03 | 24 |
GO:000758412 | Breast | IDC | response to nutrient | 29/1434 | 174/18723 | 5.69e-05 | 1.20e-03 | 29 |
GO:007135613 | Breast | IDC | cellular response to tumor necrosis factor | 35/1434 | 229/18723 | 6.64e-05 | 1.35e-03 | 35 |
GO:00434348 | Breast | IDC | response to peptide hormone | 54/1434 | 414/18723 | 8.25e-05 | 1.61e-03 | 54 |
GO:190370612 | Breast | IDC | regulation of hemopoiesis | 49/1434 | 367/18723 | 9.74e-05 | 1.86e-03 | 49 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa05165 | Liver | Cirrhotic | Human papillomavirus infection | 124/2530 | 331/8465 | 1.55e-03 | 7.83e-03 | 4.83e-03 | 124 |
hsa0516914 | Liver | Cirrhotic | Epstein-Barr virus infection | 80/2530 | 202/8465 | 1.80e-03 | 8.33e-03 | 5.13e-03 | 80 |
hsa051605 | Liver | Cirrhotic | Hepatitis C | 63/2530 | 157/8465 | 3.67e-03 | 1.49e-02 | 9.20e-03 | 63 |
hsa0514512 | Liver | Cirrhotic | Toxoplasmosis | 47/2530 | 112/8465 | 4.16e-03 | 1.63e-02 | 1.00e-02 | 47 |
hsa052126 | Liver | Cirrhotic | Pancreatic cancer | 34/2530 | 76/8465 | 4.20e-03 | 1.63e-02 | 1.00e-02 | 34 |
hsa0516410 | Liver | Cirrhotic | Influenza A | 66/2530 | 171/8465 | 8.56e-03 | 2.91e-02 | 1.79e-02 | 66 |
hsa0516714 | Liver | Cirrhotic | Kaposi sarcoma-associated herpesvirus infection | 73/2530 | 194/8465 | 1.17e-02 | 3.81e-02 | 2.35e-02 | 73 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa051651 | Liver | Cirrhotic | Human papillomavirus infection | 124/2530 | 331/8465 | 1.55e-03 | 7.83e-03 | 4.83e-03 | 124 |
hsa0516915 | Liver | Cirrhotic | Epstein-Barr virus infection | 80/2530 | 202/8465 | 1.80e-03 | 8.33e-03 | 5.13e-03 | 80 |
hsa0516012 | Liver | Cirrhotic | Hepatitis C | 63/2530 | 157/8465 | 3.67e-03 | 1.49e-02 | 9.20e-03 | 63 |
hsa0514513 | Liver | Cirrhotic | Toxoplasmosis | 47/2530 | 112/8465 | 4.16e-03 | 1.63e-02 | 1.00e-02 | 47 |
hsa0521211 | Liver | Cirrhotic | Pancreatic cancer | 34/2530 | 76/8465 | 4.20e-03 | 1.63e-02 | 1.00e-02 | 34 |
hsa0516411 | Liver | Cirrhotic | Influenza A | 66/2530 | 171/8465 | 8.56e-03 | 2.91e-02 | 1.79e-02 | 66 |
hsa0516715 | Liver | Cirrhotic | Kaposi sarcoma-associated herpesvirus infection | 73/2530 | 194/8465 | 1.17e-02 | 3.81e-02 | 2.35e-02 | 73 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0516921 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
hsa0521221 | Liver | HCC | Pancreatic cancer | 54/4020 | 76/8465 | 2.50e-05 | 1.64e-04 | 9.12e-05 | 54 |
hsa051652 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STAT1 | SNV | Missense_Mutation | novel | c.567N>C | p.Lys189Asn | p.K189N | P42224 | protein_coding | tolerated(0.43) | benign(0.014) | TCGA-A7-A3IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
STAT1 | SNV | Missense_Mutation | | c.1778N>T | p.Asp593Val | p.D593V | P42224 | protein_coding | deleterious(0.03) | benign(0.392) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
STAT1 | SNV | Missense_Mutation | | c.1236G>C | p.Gln412His | p.Q412H | P42224 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STAT1 | insertion | Nonsense_Mutation | novel | c.65_66insAGGTT | p.Tyr22Ter | p.Y22* | P42224 | protein_coding | | | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
STAT1 | insertion | Frame_Shift_Ins | novel | c.63_64insATCCCCATTTTAAAGATGAGAAAAC | p.Tyr22IlefsTer10 | p.Y22Ifs*10 | P42224 | protein_coding | | | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
STAT1 | insertion | In_Frame_Ins | novel | c.46_47insGCCTGG | p.Leu15_Glu16insGlyLeu | p.L15_E16insGL | P42224 | protein_coding | | | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STAT1 | SNV | Missense_Mutation | novel | c.431G>T | p.Ser144Ile | p.S144I | P42224 | protein_coding | tolerated(0.18) | benign(0.021) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STAT1 | SNV | Missense_Mutation | novel | c.227A>G | p.Asn76Ser | p.N76S | P42224 | protein_coding | tolerated(0.13) | benign(0.023) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STAT1 | SNV | Missense_Mutation | | c.1035N>C | p.Leu345Phe | p.L345F | P42224 | protein_coding | deleterious(0.01) | possibly_damaging(0.629) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
STAT1 | SNV | Missense_Mutation | | c.1945N>T | p.Arg649Cys | p.R649C | P42224 | protein_coding | deleterious(0.03) | possibly_damaging(0.48) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | AVT-02 UE | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | PMID26394986-Compound-10 | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | Peptidomimetic analog 5 | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | IPRIFLAVONE | IPRIFLAVONE | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | GARCINOL | GARCINOL | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | GUTTIFERONE K | GUTTIFERONE K | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | Peptide analog 8 | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | Platinum IV complexe 1 | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | Oxazole derivative 1 | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | 10-METHOXYLRUTAECARPINE | CHEMBL85826 | |